TAKS

This brand name is authorized in Cyprus, Hong Kong

Active ingredients

The drug TAKS contains one active pharmaceutical ingredient (API):

1 Diclofenac
UNII QTG126297Q - DICLOFENAC SODIUM

Diclofenac is a non-steroidal anti-inflammatory drug. The mechanism of action of diclofenac in AK may be related to the inhibition of the cycloxygenase pathway leading to reduced prostaglandin E2 (PGE2) synthesis. In addition, immunohistochemistry (IHC) from skin biopsies ac revealed that the clinical effects of diclofenac in AK are primarily due to anti-inflammatory, anti-angiogenic and possibly anti-proliferative effects and apoptosis-inducing mechanisms.

Read about Diclofenac

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
TAKS Gastro-resistant tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
TAKS Solution for injection or infusion Υπουργείο Υγείας (CY) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
M01AB05 Diclofenac M Musculo-skeletal system → M01 Antiinflammatory and antirheumatic products → M01A Antiinflammatory and antirheumatic products, non-steroids → M01AB Acetic acid derivatives and related substances
Discover more medicines within M01AB05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: HK Department of Health Drug Office Identifier(s): 26005, 57633

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.